A Multicenter, Post-marketing Surveillance Study to Monitor the Safety of Novartis Vaccine MF59-adjuvanted Influenza Subunit Vaccine FLUAD® and Sandoz Korea Vaccine MF59-adjuvanted Influenza Subunit Vaccine VANTAFLU® Administered According to the Prescribing Information in Korean Subjects Aged 65 Years or Older at the Time of Vaccination.
Phase of Trial: Phase IV
Latest Information Update: 14 Oct 2015
At a glance
- Drugs Influenza virus vaccine (Primary) ; MF 59
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Novartis; Novartis Vaccines
- 01 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2014 As per NCT study title, trial design, number of treatment arms got changed.
- 18 Nov 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.